CompletedNCT00113594
Olanzapine safety and how the body processes it in adolescents
About this title
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
Read the official source — NCT00113594Medication studyAges 13–17United States + RussiaBipolarity
Understand this study
Who was this study for?
Listed age limits: 13 years to 17 years.
- Listed locations
- Cerritos and 16 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Russia
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT00113594
- Official title
Show the full official title
Population Pharmacokinetic Study in Adolescent Patients With Schizophrenia or Bipolar I Disorder Treated With Olanzapine
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cerritos, United States · National City, United States · Poway, United States
15 more locations
- Fort Lauderdale, United States
- Eagle, United States
- Lake Charles, United States
- Glen Burnie, United States
- Albuquerque, United States
- New York, United States
- Olean, United States
- Cincinnati, United States
- Houston, United States
- Portsmouth, United States
- Kirkland, United States
- West Allis, United States
- San Juan, Puerto Rico
- Moscow, Russia
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine.
Who was this study for?
Listed age limits: 13 years to 17 years.
